Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients

References

• van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070–1090.e9. doi:10.1016/j.jpainsymman.2015.12.34027112310
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer Pain Relief. 2nd ed. Geneve: World Health Organization; 1996.
   Google Scholar
• Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000;88(3):287–294. doi:10.1016/S0304-3959(00)00339-011068116
   PubMed Web of Science ®Google Scholar
• Corli O, Montanari M, Greco MT, et al. How to evaluate the effect of pain treatments in cancer patients: results from a longitudinal outcomes and endpoint Italian cohort study. Eur J Pain. 2013;17(6):858–866. doi:10.1002/j.1532-2149.2012.00257.x23213042
   PubMed Web of Science ®Google Scholar
• Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV “real life” trial on the variability of response to opioids. Ann Oncol. 2016;27(6):1107–1115. doi:10.1093/annonc/mdw09726940689
   PubMed Web of Science ®Google Scholar
• Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage. 2001;21(2):144–150. doi:10.1016/S0885-3924(00)00228-111226765
   PubMed Web of Science ®Google Scholar
• Hanks GW, O’Neill WM, Fallon MT. Paradoxical pain. BMJ. 1993;306(6880):793. doi:10.1136/bmj.306.6880.793-b
   PubMedGoogle Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi:10.1016/S1474-4422(14)70251-025575710
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Pharmacologic management of cancer pain. Semin Oncol. 1995;22(2 Suppl 3):112–120.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68. doi:10.1016/S1470-2045(12)70040-222300860
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1–2):29–36. doi:10.1016/j.pain.2004.12.01015733628
   PubMed Web of Science ®Google Scholar
• Davies AN, Dickman A, Reid C, Stevens A-M, Zeppetella G. Science committee of the association for palliative medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–338. doi:10.1016/j.ejpain.2008.06.01418707904
   PubMed Web of Science ®Google Scholar
• Tamburini M, Rosso S, Gamba A, Mencaglia E, De Conno F, Ventafridda V. Original article: a therapy impact questionnaire for quality-of-life assessment in advanced cancer research. Ann Oncol. 1992;3(7):565–570. doi:10.1093/oxfordjournals.annonc.a0582631498079
   PubMed Web of Science ®Google Scholar
• Lucenteforte E, Vagnoli L, Pugi A, et al. A systematic review of the risk factors for clinical response to opioids for all-age patients with cancer-related pain and presentation of the paediatric STOP pain study. BMC Cancer. 2018;18(1):568. doi:10.1186/s12885-018-4478-329776346
   PubMedGoogle Scholar
• Apolone G, Corli O, Caraceni A, et al. Pattern and quality of care of cancer pain management. Results from the cancer pain outcome research study group. Br J Cancer. 2009;100(10):1566–1574. doi:10.1038/sj.bjc.660505319401688
   PubMed Web of Science ®Google Scholar
• Pasternak GW. Opiate pharmacology and relief of pain. J Clin Oncol. 2014;32(16):1655–1661. doi:10.1200/JCO.2013.53.107924799496
   PubMed Web of Science ®Google Scholar
• Corli O, Roberto A, Bennett MI, et al. Nonresponsiveness and susceptibility of opioid side effects related to cancer patients’ clinical characteristics: a post-hoc analysis. Pain Pract. 2018;18(6):748–757. doi:10.1111/papr.1266929220110
   PubMed Web of Science ®Google Scholar
• Angst MS. Intraoperative use of remifentanil for TIVA: postoperative pain, acute tolerance, and opioid-induced hyperalgesia. J Cardiothorac Vasc Anesth. 2015;29(Suppl 1):S16–S22. doi:10.1053/j.jvca.2015.01.02626025041
   PubMedGoogle Scholar
• Yu EHY, Tran DHD, Lam SW, Irwin MG. Remifentanil tolerance and hyperalgesia: short-term gain, long-term pain? Anaesthesia. 2016;71(11):1347–1362. doi:10.1111/anae.1360227734470
   PubMed Web of Science ®Google Scholar
• South SM, Smith SM. Analgesic tolerance to opioids. Pain Clin Updates. 2001;IX(5):1–4.
   Google Scholar
• Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth Analg. 2017;124(1):44–51. doi:10.1213/ANE.000000000000168327861439
   PubMed Web of Science ®Google Scholar
• Saba R, Kaye AD, Urman RD. Pharmacogenomics in pain management. Anesthesiol Clin. 2017;35(2):295–304. doi:10.1016/j.anclin.2017.01.01528526150
   PubMedGoogle Scholar
• Tanaka N, Naito T, Yagi T, Doi M, Sato S, Kawakami J. Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. Ther Drug Monit. 2014;36(3):345–352. doi:10.1097/FTD.000000000000002924365989
   PubMed Web of Science ®Google Scholar
• Luo R, Li X, Qin S, et al. Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients. Pharmacogenomics. 2017;18(18):1659–1670. doi:10.2217/pgs-2017-007229173032
   PubMed Web of Science ®Google Scholar
• Venkatasubramanian R, Fukuda T, Niu J, et al. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014;15(10):1297–1309. doi:10.2217/pgs.14.9925155932
   PubMed Web of Science ®Google Scholar
• Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One. 2014;9(1):e86114. doi:10.1371/journal.pone.008611424489693
   PubMed Web of Science ®Google Scholar
• Olesen AE, Grønlund D, Gram M, Skorpen F, Drewes AM, Klepstad P. Prediction of opioid dose in cancer pain patients using genetic profiling: not yet an option with support vector machine learning. BMC Res Notes. 2018;11(1):78. doi:10.1186/s13104-018-3194-z29374492
   PubMedGoogle Scholar
• Ladebo L, Olesen AE. Do genes affect morphine response? Pharmacogenomics. 2017;18(17):1553–1555. doi:10.2217/pgs-2017-013829061085
   PubMed Web of Science ®Google Scholar
• Fonseca F, Torrens M. Pharmacogenetics of methadone response. Mol Diagn Ther. 2018;22(1):57–78. doi:10.1007/s40291-017-0311-y29168075
   PubMed Web of Science ®Google Scholar
• Owusu Obeng A, Hamadeh I, Smith M. Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy. 2017;37(9):1105–1121. doi:10.1002/phar.198628699646
   PubMed Web of Science ®Google Scholar
• Ren Z-Y, Xu X-Q, Bao Y-P, et al. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Physician. 2015;18(2):131–152.25794200
   PubMed Web of Science ®Google Scholar
• Currow DC, Quinn S, Ekstrom M, et al. Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors? BMJ Open. 2015;5(5):e006818. doi:10.1136/bmjopen-2014-006818
   PubMed Web of Science ®Google Scholar
• Bauer IE, Soares JC, Nielsen DA. The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: a systematic review. Am J Addict. 2015;24(1):15–23. doi:10.1111/ajad.1217225823631
   PubMed Web of Science ®Google Scholar
• Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. 2018;19(8):499–514. doi:10.1038/s41583-018-0028-x29934561
   PubMed Web of Science ®Google Scholar
• Shang Y, Filizola M. Opioid receptors: structural and mechanistic insights into pharmacology and signaling. Eur J Pharmacol. 2015;763(Pt B):206–213. doi:10.1016/j.ejphar.2015.05.01225981301
   PubMed Web of Science ®Google Scholar
• Giron SE, Bjurstrom MF, Griffis CA, et al. Increased central nervous system interleukin-8 in a majority postlaminectomy syndrome chronic pain population. Pain Med. 2018;19(5):1033–1043. doi:10.1093/pm/pnx12629016958
   PubMed Web of Science ®Google Scholar
• Giron SE, Griffis CA, Burkard JF. Chronic pain and decreased opioid efficacy: an inflammatory link. Pain Manag Nurs. 2015;16(5):819–831. doi:10.1016/j.pmn.2015.04.00125962543
   PubMed Web of Science ®Google Scholar